Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.


Main focus: In vitro and in vivo delivery solutions for genome-editing molecules/therapeutics (CRISPR-Cas ribonucleoproteins (RNPs))

Company stage: Pre-clinical

Diseases : Rare cancer (Hairy cell leukaemia), other rare diseases (Cystic Fibrosis, Haemophilia)

Our novel delivery system: Engineered biomolecule (non-viral, non-nanoparticle, non-lipid)

Funding stage: Seed


CYGENICA LIMITED, 12 South Mall, Co. Cork (Ireland)

R & D Innovation Lab at 700 NIP, NCL Innovation Park, Dr. Homi Bhabha Road, Pashan, Pune – 411 008 (India)


At CyGenica, we focus on enhanced quality of life and improved patient outcome by enabling safe, targeted, and affordable intracellular delivery of therapeutic molecules. Our platform is a non-toxic proprietary engineered biomolecule that works just like a molecular drill. It bores through the cell membrane to deliver molecular cargoes to the nucleus without causing any harm to the cell, thus solving the most crucial issue of targeted intracellular delivery. We use our platform to develop in vitro and in vivo delivery solutions with a particular focus on cancer therapies and gene-editing components (CRISPR-Cas ribonucleproteins (RNPs)).


HashtagCompany FeaturedHashtagCyGenica

Company: CyGenica
Search CRISPR Medicine